An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic Cancer
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
Thierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX (mFOLFIRINOX) regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
While gemcitabine has been the standard of care since 2008, a mFOLFIRINOX regimen of fluorouracil (5-FU), oxaliplatin, leucovorin, and irinotecan was developed in France to show superiority. While it was superior to gemcitabine in metastatic disease, it was still too toxic for use in the adjuvant setting.
Bolus 5-FU is suppressed in the mFOLFIRINOX regimen and instead continuous infusion of 5-FU is used with the other agents. In this trial, mFOLFIRINOX was compared to gemcitabine in patients 3 to 12 weeks after surgery for 6 months.
See more information on thispractice-changing trial in pancreatic cancer and the results
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
